Skip to main content

Table 1 Eligibility criteria

From: The REFLO-STEMI trial comparing intracoronary adenosine, sodium nitroprusside and standard therapy for the attenuation of infarct size and microvascular obstruction during primary percutaneous coronary intervention: study protocol for a randomised controlled trial

Inclusion criteria Exclusion criteria
Aged ≥18 years Contraindications to: P-PCI, CMRI, gadolinium-based and/or iodinated contrast agents, or study medications: Adenosine, SNP, Aspirin, Thienopyridine and Bivalirudin
Informed ASSENT (verbal consent) prior to angiography
STEMI ≤6 h of symptom onset, requiring P-PCI
SBP ≤90 mmHg
Single-vessel coronary artery disease (non-culprit disease <70% stenosis at angiography) Cardiogenic shock
Previous Q wave myocardial infarction
Culprit lesion not identified or located in a bypass graft
TIMI flow 0/1 at angiography
Stent thrombosis
QTc <450 ms Left main disease
Known severe asthma
Known stage 4 or 5 chronic kidney disease (eGFR <30 mL/min/1.73 m2)
  1. CMRI, cardiac magnetic resonance imaging; e-GFR, estimated glomerular filtration rate; P-PCI, primary percutaneous coronary intervention; SBP, systolic blood pressure; TIMI, Thrombolysis in Myocardial Infarction.